document.write('
Pharma\'s Cutting Edge
Pharmaceutical and biotech science and business
The end of PCE?
In case you are one of the folks who subscribe to my RSS feed or just found the site and were wondering why there have been no posts since April, this note\'s for you. Here\'s the truth.  I enjoy writing the occasional editorial on our industry, and I especially enjoy it ...
Provenge success definitive now it seems
I last wrote about Dendreon\'s Provenge active immunotherapy for prostate cancer back in May of 2007, when I raised questions about FDA\'s decision not to approve the therapy, despite a favorable advisory committee opinion. Today, I am happy to pass along news of positive top-line results from a confirmatory Phase 3 ...
A case study of publication bias
Have a look at a recent paper by an osteopath with strong anti-industry sentiment who nevertheless manages to put together a study that systematically (and mostly fairly) examines the biases evident among published reviews of rimonabant. I say "mostly fairly", because I found the editorializing to be all over the place, an anti-industry ...
');